Oculis Holding Ag (OCS)

$31.00 +3.09 (11.07%)
Market Cap 1.62B
Revenue (ttm) 1.45M
Net Income (ttm) -119.44M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -8,237.24%
Debt to Equity Ratio 0.00
Volume 966,000
Avg Vol 363,480
Day's Range N/A - N/A
Shares Out 57.98M
Stochastic %K 51%
Beta 0.38
Analysts Strong Sell
Price Target $50.11

Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease m...

Industry: Biotechnology
Sector: Healthcare
Phone: 41 41 711 3960
Website: oculis.com
Address:
Bahnhofstrasse 20, Zug, Switzerland
justiceforb_85
justiceforb_85 May. 22 at 7:01 AM
$OCS looking forward to OCS-01 data release (likely in June).
0 · Reply
Champi2305
Champi2305 May. 21 at 2:34 PM
$OCS $75 https://www.marketscreener.com/news/guggenheim-initiates-oculis-holding-at-buy-with-75-price-target-ce7f5adeda8cf121
0 · Reply
Champi2305
Champi2305 May. 20 at 5:40 PM
$OCS Ready for a rebound on 20 wma. As usual.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser May. 19 at 8:14 PM
$OCS RSI: 55.40, MACD: 0.6473 Vol: 2.03, MA20: 28.83, MA50: 27.42 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Champi2305
Champi2305 May. 13 at 12:20 PM
$OCS
0 · Reply
justiceforb_85
justiceforb_85 May. 12 at 3:58 AM
$OCS holding steady until OCS-01 update in June.
0 · Reply
PlutoAnalyses
PlutoAnalyses May. 11 at 11:42 PM
$OCS Earnings Takeaways: - Still on track for June DIAMOND release - Cash to reach by 2H 2029 (This is a bunker) Regarding OCS potential market, 70% of a recent study agreed they would start therapy with a non-invasive treatment after a 5-letter BCVA vision loss.
0 · Reply
Scratcher
Scratcher May. 10 at 4:59 PM
$OCS should see a nice run into June
0 · Reply
Scratcher
Scratcher May. 10 at 3:19 PM
$OCS breakout coming
0 · Reply
OpenOutcrier
OpenOutcrier May. 7 at 12:50 PM
$OCS (+3.1% pre) Oculis gets FDA agreement on study design for optic neuritis drug https://ooc.bz/l/101502
0 · Reply
Latest News on OCS
Oculis initiated with a Buy at Guggenheim

2026-05-20T20:15:09.000Z - 1 day ago

Oculis initiated with a Buy at Guggenheim

Oculis price target raised to $42 from $38 at JPMorgan

2026-05-18T11:45:55.000Z - 3 days ago

Oculis price target raised to $42 from $38 at JPMorgan

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

May 15, 2026, 4:05 PM EDT - 6 days ago

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors

May 14, 2026, 4:05 PM EDT - 7 days ago

Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors

Oculis Holding AG Transcript: AGM 2026

May 13, 2026, 6:00 AM EDT - 8 days ago

Oculis Holding AG Transcript: AGM 2026

Oculis Holding AG Slides: FY 2026

May 13, 2026, 6:00 AM EDT - 8 days ago

Oculis Holding AG Slides: FY 2026

Oculis price target raised to $47 from $44 at H.C. Wainwright

2026-05-12T17:40:18.000Z - 9 days ago

Oculis price target raised to $47 from $44 at H.C. Wainwright

Oculis price target raised to $44 from $43 at BofA

2026-05-12T14:11:25.000Z - 9 days ago

Oculis price target raised to $44 from $43 at BofA

Oculis reports Q1 EPS (49c), consensus (41c)

2026-05-11T23:11:34.000Z - 10 days ago

Oculis reports Q1 EPS (49c), consensus (41c)

Oculis Reports Q1 2026 Financial Results and Provides Company Update

May 11, 2026, 4:05 PM EDT - 10 days ago

Oculis Reports Q1 2026 Financial Results and Provides Company Update

Oculis Holding AG Earnings release: Q1 2026

May 11, 2026, 1:00 AM EDT - 11 days ago

Oculis Holding AG Earnings release: Q1 2026

Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial

May 7, 2026, 4:57 AM EDT - 15 days ago

Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial

Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting

May 5, 2026, 4:00 AM EDT - 17 days ago

Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting

Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

May 1, 2026, 4:00 AM EDT - 21 days ago

Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Oculis Publishes Invitation to the Annual General Meeting

Apr 21, 2026, 4:05 PM EDT - 4 weeks ago

Oculis Publishes Invitation to the Annual General Meeting

Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema

Apr 20, 2026, 4:00 AM EDT - 4 weeks ago

Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema

Oculis Holding AG Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 14, 2026, 9:30 AM EDT - 5 weeks ago

Oculis Holding AG Transcript: 25th Annual Needham Virtual Healthcare Conference

Oculis to Participate in Upcoming Investor Conferences

Apr 7, 2026, 4:00 AM EDT - 6 weeks ago

Oculis to Participate in Upcoming Investor Conferences

Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis

Mar 31, 2026, 5:00 AM EDT - 7 weeks ago

Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis

Three new option listings on March 17th

2026-03-17T12:36:27.000Z - 2 months ago

Three new option listings on March 17th

GBFH SION

Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting

Mar 16, 2026, 5:00 AM EDT - 2 months ago

Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting

Oculis Holding AG Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 10:40 AM EDT - 2 months ago

Oculis Holding AG Transcript: Leerink Global Healthcare Conference 2026

Oculis price target raised to $50 from $40 at Stifel

2026-03-05T11:47:22.000Z - 2 months ago

Oculis price target raised to $50 from $40 at Stifel

Oculis Publishes 2025 Consolidated Financial Statements

Mar 5, 2026, 4:00 AM EST - 2 months ago

Oculis Publishes 2025 Consolidated Financial Statements

Oculis files automatic mixed securities shelf

2026-03-04T21:25:18.000Z - 2 months ago

Oculis files automatic mixed securities shelf

Oculis price target raised to $44 from $42 at H.C. Wainwright

2026-03-04T17:05:50.000Z - 2 months ago

Oculis price target raised to $44 from $42 at H.C. Wainwright

Oculis reports Q4 EPS (CHF 0.42c) vs. (CHF 0.67) last year

2026-03-03T21:38:54.000Z - 2 months ago

Oculis reports Q4 EPS (CHF 0.42c) vs. (CHF 0.67) last year

Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Company Update

Mar 3, 2026, 4:05 PM EST - 2 months ago

Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Company Update

Oculis Holding AG Annual report: Q4 2025

Mar 3, 2026, 4:00 PM EST - 2 months ago

Oculis Holding AG Annual report: Q4 2025

Oculis Holding AG Earnings release: Q4 2025

Mar 3, 2026, 4:00 PM EST - 2 months ago

Oculis Holding AG Earnings release: Q4 2025

Oculis Holding AG Annual report: Q4 2025

Mar 3, 2026, 4:00 PM EST - 2 months ago

Oculis Holding AG Annual report: Q4 2025

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated

Feb 18, 2026, 4:05 PM EST - 3 months ago

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated

Oculis Appoints Katie Kazem as Chief Legal Officer

Feb 17, 2026, 4:00 AM EST - 3 months ago

Oculis Appoints Katie Kazem as Chief Legal Officer

Oculis Holding AG Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 4:30 PM EST - 4 months ago

Oculis Holding AG Transcript: 44th Annual J.P. Morgan Healthcare Conference

Oculis Holding AG Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 4:30 PM EST - 4 months ago

Oculis Holding AG Slides: 44th Annual J.P. Morgan Healthcare Conference

Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare Conference

Jan 8, 2026, 4:00 AM EST - 4 months ago

Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare Conference

Oculis up 9% after announcing breakthrough therapy designation for Privosegtor

2026-01-06T12:55:18.000Z - 4 months ago

Oculis up 9% after announcing breakthrough therapy designation for Privosegtor

Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis

Jan 6, 2026, 4:00 AM EST - 4 months ago

Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis

Oculis price target raised to $40 from $35 at Stifel

2025-12-19T12:50:26.000Z - 5 months ago

Oculis price target raised to $40 from $35 at Stifel

Oculis initiated with an Overweight at JPMorgan

2025-12-19T10:50:12.000Z - 5 months ago

Oculis initiated with an Overweight at JPMorgan

Oculis initiated with an Outperform at LifeSci Capital

2025-12-03T12:15:09.000Z - 6 months ago

Oculis initiated with an Outperform at LifeSci Capital

Oculis price target lowered to $29 from $30 at BofA

2025-11-13T14:55:28.000Z - 6 months ago

Oculis price target lowered to $29 from $30 at BofA

Oculis Holding AG Transcript: Stifel 2025 Healthcare Conference

Nov 12, 2025, 2:00 PM EST - 6 months ago

Oculis Holding AG Transcript: Stifel 2025 Healthcare Conference

Oculis Holding AG Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 11, 2025, 12:30 PM EST - 6 months ago

Oculis Holding AG Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Oculis price target raised to $42 from $36 at H.C. Wainwright

2025-11-11T11:25:58.000Z - 6 months ago

Oculis price target raised to $42 from $36 at H.C. Wainwright

Oculis Reports Q3 2025 Financial Results and Provides Company Update

Nov 10, 2025, 4:05 PM EST - 6 months ago

Oculis Reports Q3 2025 Financial Results and Provides Company Update

Oculis Holding AG Earnings release: Q3 2025

Nov 10, 2025, 4:00 PM EST - 6 months ago

Oculis Holding AG Earnings release: Q3 2025

Oculis Holding AG Registration statement: Registration Filing

Nov 10, 2025, 7:00 AM EST - 6 months ago

Oculis Holding AG Registration statement: Registration Filing

Oculis to Participate in Upcoming November Investor Conferences

Nov 5, 2025, 4:00 AM EST - 7 months ago

Oculis to Participate in Upcoming November Investor Conferences

Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development

Oct 30, 2025, 4:30 AM EDT - 7 months ago

Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development

Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025

Oct 14, 2025, 4:00 AM EDT - 7 months ago

Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025

Oculis Holding AG Transcript: Status Update

Oct 6, 2025, 8:30 AM EDT - 8 months ago

Oculis Holding AG Transcript: Status Update

Oculis Holding AG Press release: Status Update

Oct 6, 2025, 8:30 AM EDT - 8 months ago

Oculis Holding AG Press release: Status Update

Oculis Holding AG Slides: Status Update

Oct 6, 2025, 8:30 AM EDT - 8 months ago

Oculis Holding AG Slides: Status Update

Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy

Oct 6, 2025, 4:07 AM EDT - 8 months ago

Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy

Oculis Publishes Notification of Transactions by Person Discharging Managerial Responsibilities

Sep 26, 2025, 4:05 PM EDT - 8 months ago

Oculis Publishes Notification of Transactions by Person Discharging Managerial Responsibilities

Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS

Sep 22, 2025, 4:00 AM EDT - 8 months ago

Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS

Oculis Holding AG Transcript: Baird Global Healthcare Conference 2025

Sep 9, 2025, 3:45 PM EDT - 9 months ago

Oculis Holding AG Transcript: Baird Global Healthcare Conference 2025

Oculis Holding AG Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 2:30 PM EDT - 9 months ago

Oculis Holding AG Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025

Sep 4, 2025, 1:00 PM EDT - 9 months ago

Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025

Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences

Sep 1, 2025, 4:00 AM EDT - 9 months ago

Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences

Oculis to Participate in Upcoming September Investor Conferences

Aug 28, 2025, 4:00 AM EDT - 9 months ago

Oculis to Participate in Upcoming September Investor Conferences

Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D.

Aug 25, 2025, 4:00 AM EDT - 9 months ago

Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D.

Oculis Reports Q2 2025 Financial Results and Provides Company Update

Aug 21, 2025, 4:05 PM EDT - 9 months ago

Oculis Reports Q2 2025 Financial Results and Provides Company Update

Oculis Holding AG Earnings release: Q2 2025

Aug 21, 2025, 4:00 PM EDT - 9 months ago

Oculis Holding AG Earnings release: Q2 2025

Oculis Holding AG Transcript: Fireside Chat

Aug 13, 2025, 11:00 AM EDT - 10 months ago

Oculis Holding AG Transcript: Fireside Chat

Oculis Holding AG Transcript: H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 13, 2025, 7:00 AM EDT - 10 months ago

Oculis Holding AG Transcript: H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Oculis to Participate in Upcoming H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 12, 2025, 4:00 AM EDT - 10 months ago

Oculis to Participate in Upcoming H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Oculis to Participate in Upcoming H.C Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 12, 2025, 4:00 AM EDT - 10 months ago

Oculis to Participate in Upcoming H.C Wainwright 5th Annual Ophthalmology Virtual Conference

Oculis Upsized Loan Facility to Access up to CHF 100 million

Aug 1, 2025, 4:00 AM EDT - 10 months ago

Oculis Upsized Loan Facility to Access up to CHF 100 million

Oculis Publishes Results of 2025 Annual General Meeting

Jun 5, 2025, 4:00 AM EDT - 1 year ago

Oculis Publishes Results of 2025 Annual General Meeting

Oculis to Participate in Upcoming June Investor Conferences

Jun 3, 2025, 4:00 AM EDT - 1 year ago

Oculis to Participate in Upcoming June Investor Conferences

Oculis Holding AG Transcript: Stifel 2025 Virtual Ophthalmology Forum

May 27, 2025, 1:00 PM EDT - 1 year ago

Oculis Holding AG Transcript: Stifel 2025 Virtual Ophthalmology Forum

Oculis Holding AG Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 20, 2025, 9:30 AM EDT - 1 year ago

Oculis Holding AG Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

Oculis Holding AG Transcript: BofA Securities 2025 Healthcare Conference

May 14, 2025, 6:00 PM EDT - 1 year ago

Oculis Holding AG Transcript: BofA Securities 2025 Healthcare Conference

Oculis Reports Q1 2025 Financial Results and Provides Company Update

May 8, 2025, 4:05 PM EDT - 1 year ago

Oculis Reports Q1 2025 Financial Results and Provides Company Update

Oculis Reports Q1 Financial Results and Provides Company Update

May 8, 2025, 4:05 PM EDT - 1 year ago

Oculis Reports Q1 Financial Results and Provides Company Update

Oculis Holding AG Earnings release: Q1 2025

May 8, 2025, 4:00 PM EDT - 1 year ago

Oculis Holding AG Earnings release: Q1 2025

Oculis to Present at Upcoming May Investor Conferences

May 7, 2025, 4:00 AM EDT - 1 year ago

Oculis to Present at Upcoming May Investor Conferences

Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences

May 1, 2025, 4:00 AM EDT - 1 year ago

Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences

Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences

May 1, 2025, 4:00 AM EDT - 1 year ago

Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences

Oculis Updates Share Capital

Apr 25, 2025, 4:00 PM EDT - 1 year ago

Oculis Updates Share Capital

Oculis and EURETINA Announce the 2025 Ramin Tadayoni Award

Apr 17, 2025, 5:00 AM EDT - 1 year ago

Oculis and EURETINA Announce the 2025 Ramin Tadayoni Award

Oculis Holding AG Transcript: R&D Day 2025

Apr 15, 2025, 10:00 AM EDT - 1 year ago

Oculis Holding AG Transcript: R&D Day 2025

Oculis Holding AG Slides: FY 2025

Apr 15, 2025, 10:00 AM EDT - 1 year ago

Oculis Holding AG Slides: FY 2025

Oculis Hosts R&D Event Today to Showcase Progress on All Three Pipeline Assets

Apr 15, 2025, 4:00 AM EDT - 1 year ago

Oculis Hosts R&D Event Today to Showcase Progress on All Three Pipeline Assets

Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema

Apr 10, 2025, 8:00 AM EDT - 1 year ago

Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema

Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema

Apr 10, 2025, 4:00 AM EDT - 1 year ago

Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema

Oculis to Host In-Person and Virtual R&D Day on Key Business Updates and the Development Plans for Privosegtor (OCS-05) in Acute Optic Neuritis and Beyond

Apr 1, 2025, 4:00 AM EDT - 1 year ago

Oculis to Host In-Person and Virtual R&D Day on Key Business Updates and the Development Plans for Privosegtor (OCS-05) in Acute Optic Neuritis and Beyond

Oculis Publishes Notifications of Transactions by Person Discharging Managerial Responsibilities

Mar 20, 2025, 6:01 PM EDT - 1 year ago

Oculis Publishes Notifications of Transactions by Person Discharging Managerial Responsibilities

Oculis Reports Q4 and Full Year 2024 Financial Results and Provides Company Update

Mar 11, 2025, 4:30 PM EDT - 1 year ago

Oculis Reports Q4 and Full Year 2024 Financial Results and Provides Company Update

Oculis Holding AG Earnings release: Q4 2024

Mar 11, 2025, 4:00 PM EDT - 1 year ago

Oculis Holding AG Earnings release: Q4 2024

Oculis Holding AG Annual report: Q4 2024

Mar 11, 2025, 4:00 PM EDT - 1 year ago

Oculis Holding AG Annual report: Q4 2024

Oculis Holding AG Transcript: Leerink's Global Healthcare Conference 2025

Mar 11, 2025, 3:00 PM EDT - 1 year ago

Oculis Holding AG Transcript: Leerink's Global Healthcare Conference 2025

Oculis to Present at Upcoming March Investor Conference

Mar 5, 2025, 4:00 AM EST - 1 year ago

Oculis to Present at Upcoming March Investor Conference

Oculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares

Feb 13, 2025, 7:40 PM EST - 1 year ago

Oculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares

Oculis updates share capital for its existing at-the-market offering program

Jan 31, 2025, 4:00 PM EST - 1 year ago

Oculis updates share capital for its existing at-the-market offering program

justiceforb_85
justiceforb_85 May. 22 at 7:01 AM
$OCS looking forward to OCS-01 data release (likely in June).
0 · Reply
Champi2305
Champi2305 May. 21 at 2:34 PM
$OCS $75 https://www.marketscreener.com/news/guggenheim-initiates-oculis-holding-at-buy-with-75-price-target-ce7f5adeda8cf121
0 · Reply
Champi2305
Champi2305 May. 20 at 5:40 PM
$OCS Ready for a rebound on 20 wma. As usual.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser May. 19 at 8:14 PM
$OCS RSI: 55.40, MACD: 0.6473 Vol: 2.03, MA20: 28.83, MA50: 27.42 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Champi2305
Champi2305 May. 13 at 12:20 PM
$OCS
0 · Reply
justiceforb_85
justiceforb_85 May. 12 at 3:58 AM
$OCS holding steady until OCS-01 update in June.
0 · Reply
PlutoAnalyses
PlutoAnalyses May. 11 at 11:42 PM
$OCS Earnings Takeaways: - Still on track for June DIAMOND release - Cash to reach by 2H 2029 (This is a bunker) Regarding OCS potential market, 70% of a recent study agreed they would start therapy with a non-invasive treatment after a 5-letter BCVA vision loss.
0 · Reply
Scratcher
Scratcher May. 10 at 4:59 PM
$OCS should see a nice run into June
0 · Reply
Scratcher
Scratcher May. 10 at 3:19 PM
$OCS breakout coming
0 · Reply
OpenOutcrier
OpenOutcrier May. 7 at 12:50 PM
$OCS (+3.1% pre) Oculis gets FDA agreement on study design for optic neuritis drug https://ooc.bz/l/101502
0 · Reply
Champi2305
Champi2305 May. 7 at 9:20 AM
$OCS https://investors.oculis.com/news-releases/news-release-details/oculis-announces-agreement-fda-special-protocol-assessment-spa/
0 · Reply
Champi2305
Champi2305 May. 6 at 12:59 PM
$OCS https://clinicaltrials.gov/study/NCT05066997 https://clinicaltrials.gov/study/NCT06172257 Completed
0 · Reply
Merlintrader
Merlintrader May. 5 at 7:56 PM
$OCS
0 · Reply
Champi2305
Champi2305 May. 5 at 10:21 AM
$OCS https://investors.oculis.com/news-releases/news-release-details/latest-findings-dme-aware-delphi-study-presented-arvo-2026/
0 · Reply
Merlintrader
Merlintrader May. 5 at 10:16 AM
$OCS Oculis Holding AG (Nasdaq: $OCS): the June 2026 DIAMOND readout is the real test https://www.merlintrader.com/oculis-holdings-may2026-deepdive/
0 · Reply
justiceforb_85
justiceforb_85 Apr. 28 at 10:31 PM
$OCS look forward to P3 data for OCS-01 in DME.
0 · Reply
DianeChristmas423
DianeChristmas423 Apr. 27 at 7:31 PM
$OCS low liquidity feel, tape changes fast if volume finally shows
0 · Reply
laaarsas
laaarsas Apr. 27 at 11:02 AM
$OCS Seems like market could be pricing this too high
0 · Reply
laaarsas
laaarsas Apr. 25 at 2:03 PM
$OCS I think I lean towards ph3 success but for me there are many factors that are hard to assess here, much is unknown. Might stay outside of this one.
0 · Reply
laaarsas
laaarsas Apr. 25 at 1:31 PM
$OCS One of the hardest questions for me to answer is what effect size the market is expecting. What bar do we need to reach to be considered to have a clear win?
1 · Reply
laaarsas
laaarsas Apr. 25 at 12:19 PM
$OCS I'm not getting this case. Ok eye drops for DME seems interesting. But I see data risk. Confidence intervals are broad. Ph2 data set with worse BCVA... mean for entire ph2 was 64 BCVA. For stage 1 it was 58. Is the difference that big? Does it really explain the results? Or is it at post-hoc signal? I think there is too much incertainty for me dig deeper here... might look somewhere else... I would not be surprised if it works, but also the other way around. The entry does not seem so obvious at face value? What do you think? Seems current data is very varying... I don't know I think this one is a bit hard?
1 · Reply
laaarsas
laaarsas Apr. 25 at 1:52 AM
$OCS I don’t get it. They will never be able to compete with aVEGF efficacy-wise in DME. What’s their niche?
0 · Reply